Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $18.4 million.

  • Crinetics Pharmaceuticals' Other Non-Current Assets rose 131784.62% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 131784.62%. This contributed to the annual value of $2.8 million for FY2024, which is 4145.0% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Other Non-Current Assets is $18.4 million, which was up 131784.62% from $14.9 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Other Non-Current Assets ranged from a high of $18.4 million in Q3 2025 and a low of $500000.0 during Q1 2021
  • Moreover, its 5-year median value for Other Non-Current Assets was $1.3 million (2022), whereas its average is $3.5 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Other Non-Current Assets fell by 7.69% in 2024 and then soared by 131784.62% in 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $500000.0 in 2021, then surged by 160.2% to $1.3 million in 2022, then soared by 53.73% to $2.0 million in 2023, then surged by 41.45% to $2.8 million in 2024, then surged by 551.54% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q3 2025, $14.9 million for Q2 2025, and $14.2 million during Q1 2025.